The results indicate better overall survival in young triple-negative patients with pathogenic germline variants in BRCA1 or BRCA2 compared to triple-negative breast cancer without pathogenic variants, but not for other clinical subtypes. The gene discussed is BRCA2; the disease is triple-negative breast carcinoma.